Publish your oncology research
Our high-impact oncology journals disseminate cutting-edge data to physicians, medical researchers, and healthcare professionals around the world supporting revolutionary treatments and research advances.
We work with all of the top 10 largest drug companies ranked by Forbes¹ and 86% of the top 50 global pharma companies ranked by Pharmaceutical Executive.²
Our oncology portfolio in the fields of immunology and hematology champions the most relevant, up-to-date, and scientifically sound research on topics such as:
- Cancer immunology and immunotherapies
- Common and rare blood diseases
- Drug development and research (including orphan drugs)
- Inflammation in cancer
Like you, we value high visibility and timely publication. To extend your research impact, publish open access and use our Accelerated Publication service, which fast-tracks your article from submission to online publication in as little as three weeks. Help your article reach non-specialist audiences by publishing a Plain Language Summary (PLS).
Interested in publishing with us?
Our editorial team is happy to speak with you about the best options for your paper.
An international forum for publication of high-quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies.
2020 Impact Factor: 3.28‡
Expert appraisal and commentary on the major trends in cancer care, highlighting the performance of new therapeutic and diagnostic approaches.
2020 Impact Factor: 4.512‡
International, peer-reviewed, open access journal. Focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient.
2020 Impact Factor: 3.989‡
Timely original research, reviews, and op-ed pieces on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy.
2020 Impact Factor: 4.742‡
Impact Factor: 2.176‡
Impact Factor: 8.11‡
Journal of Hepatocellular Carcinoma*§
Impact Factor: 5.828‡
Impact Factor: 4.089‡
Cancer Biology & Therapy
Impact Factor: 4.742‡
Expert Review of Anticancer Therapy†
Impact Factor: 4.512‡
OncoTargets and Therapy*§
Impact Factor: 4.147‡
Leukemia and Lymphoma
Impact Factor: 3.28‡
Cancer Management and Research*§
Impact Factor: 3.989‡
Nutrition and Cancer
Impact Factor: 2.9‡
Impact Factor: 2.176‡
Journal of Chemotherapy
Impact Factor: 1.714‡
Lung Cancer: Targets and Therapy*§
Breast Cancer: Targets and Therapy*§
*Fully open access journal.
†Offers Accelerated Publication.
‡Copyright: 2019 Journal Citation Reports®, Clarivate Analytics, 2020.
§Published by Dove Medical Press.
Why publish with Taylor & Francis?
Research articles are assessed by independent peer reviewers for quality, validity, and relevance. Many journals in our medical portfolio are indexed in the Science Citation Index, Science Citation Index Expanded, Scopus, and MEDLINE.
Contributors to our medical journals benefit from direct and prompt communication with in-house editorial specialists.
Taylor & Francis publishes research from top pharmaceutical companies like Pfizer, Roche, GlaxoSmithKline, and Sanofi.